Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
R-327 by Recce Pharmaceuticals for Urinary Tract Infections: Likelihood of Approval
R-327 is under clinical development by Recce Pharmaceuticals and currently in Phase II for Urinary Tract Infections. According to GlobalData,...
Data Insights
R-327 by Recce Pharmaceuticals for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval
R-327 is under clinical development by Recce Pharmaceuticals and currently in Phase I for Influenza A Virus, H1N1 Subtype Infections....